To identify genomic alterations in CRC that correlate with the response to anti-PD-1 monotherapy, we performed whole exome sequencing (WES) of metastatic CRC samples from 13 patients with complete clinical prognostic information (Figure 1A). The gene discussed is PDCD1; the disease is colorectal carcinoma.